| Document |
Document Title |
|
WO/2022/233891A1 |
The present invention relates to a process for the production of an antibacterial compound suitable for use in the treatment of infection with, or disease caused or exacerbated by, Gram-negative bacteria of the order Enterobacterales and...
|
|
WO/2022/236139A1 |
Crystalline forms of N-{3-[(1S)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}eth
yl]-phenyl}-5-methylpyridine-3-carboxamide are provided. Pharmaceutical compositions and dosage forms containing the crystal forms are also provided, inclu...
|
|
WO/2022/235900A1 |
Provided herein are methods of treating, preventing, managing, and/or ameliorating acute myeloid leukemia or myelodysplastic syndrome comprising administering N-((R)-l-(3- chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((S)-2,6-dioxopi
peri...
|
|
WO/2022/235558A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression...
|
|
WO/2022/235220A1 |
Disclosed herein are two compounds that are used together to form a PROTAC molecule in situ. Thus, there is a compound of formula Ia and a compound of formula Ib: where R1, R2, L1, L2, X and Y are described herein.
|
|
WO/2022/232919A1 |
The present application relates to compounds, and uses thereof for example for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating a viral infection or disease. In an embodi...
|
|
WO/2022/235717A1 |
Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.
|
|
WO/2022/236101A1 |
Isoquinolinone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell...
|
|
WO/2022/233727A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to met...
|
|
WO/2022/235859A1 |
Novel compounds of structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of ...
|
|
WO/2022/235440A1 |
Method of treating a traumatic brain injury, a spinal cord injury, or stroke using small molecule CCR2 inhibitors. Also disclosed are kits and therapeutic uses of the small molecule CCR2 inhibitors.
|
|
WO/2022/235715A1 |
Provided herein are compounds for inhibiting and/or degrading IL-2 inducible T-cell kinase (ITK), compositions comprising the compounds, methods of making the same, and methods of their use for treating diseases or disorders including ca...
|
|
WO/2022/235565A1 |
The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by aberrant activity of at least one class IIa histone deacetylase (HDAC4/5/7/9).
|
|
WO/2022/233886A1 |
The present invention relates to an antibacterial compound, and its use in the treatment of infection with, or disease caused or exacerbated by, Gram-negative bacteria of the order Enterobacterales and/or Gram-negative bacteria of the ge...
|
|
WO/2022/234193A1 |
The present invention relates to compounds of formula (I),to salts, solvates and solvates of salts thereof, and to pharmaceutical compositions comprising these compounds as active ingredients. The invention further relates to their use a...
|
|
WO/2022/236118A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of compounds that modulate a target in the brain including sphingosine- 1 -phosphate receptor (S1P1), lysophosphatidic acid receptor 1 (LPA1), G-protein coupled receptor 120 ...
|
|
WO/2022/233264A1 |
The present invention relates to a class of xanthine oxidase inhibitors, which are compounds as represented by general formula (I) or pharmaceutically acceptable salts thereof. The xanthine oxidase inhibitors have an excellent xanthine o...
|
|
WO/2022/226667A1 |
The present application relates to substituted heterocyclic compounds of Formula (I) and substituted compound of Formula (II): (I) (II) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising th...
|
|
WO/2022/228547A1 |
Provided are the compound shown in general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or co-crystal thereof, an intermediate thereof, and a use thereof in...
|
|
WO/2022/232391A1 |
Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may bind to CRBN complex and cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containi...
|
|
WO/2022/232333A1 |
Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, L, X and Y are as defined herein. The compounds of Formula (I) act as IL4I1 inhibitors and can be useful in preventi...
|
|
WO/2022/229341A1 |
The present invention relates to heterocyclic compounds of formula (I) capable of activat-ing STING (Stimulator of Interferon Genes).
|
|
WO/2022/232459A1 |
This application relates to novel triazole-pyridine substituted pyrrolidinyl, tetrahydro-2H-pyranyl, cyclohexyl, and piperidinyl acetic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medi...
|
|
WO/2022/227032A1 |
Provided herein is a method for preparing novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation.
|
|
WO/2022/227015A1 |
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related disea...
|
|
WO/2022/229458A1 |
The present disclosure provides a compound of Formula (II), wherein R1 is an optionally substituted mono or bicyclic saturated, partly unsaturated or aromatic heterocyclyl comprising at least one nitrogen atom, and the other variables ar...
|
|
WO/2022/228549A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of a disorder, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2022/228286A1 |
The present invention relates to the field of medicinal chemistry, and disclosed are a class of biphenyl derivatives having PD-1/PD-L1 inhibitory activity, a preparation method therefor and a use thereof. Further disclosed are a composit...
|
|
WO/2022/229684A1 |
A process for preparing a chlorpheniramine maleate, comprising addition of a predetermined amount of an isopropyl alcohol and a maleic acid to obtain a mixture, heating the isopropyl alcohol and the maleic acid mixture at a predetermined...
|
|
WO/2022/232838A1 |
The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), ...
|
|
WO/2022/226668A1 |
The present application relates to halo-substituted heterocyclic compounds of Formula (I): or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable ...
|
|
WO/2022/230912A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The present inventors hav...
|
|
WO/2022/228387A1 |
Provided are certain PARP inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2022/228556A1 |
Provided herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation. It also provides pharmaceu...
|
|
WO/2022/231410A1 |
The invention relates to new radiopharmaceuticals that inhibit fibroblast activation protein (iFAP), which are based on the molecule ((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl)pyrrolidin-2-yl)bo
ronic acid (HYNIC-iFAP), wherein the nitrog...
|
|
WO/2022/228576A1 |
A protein regulator-targeted compound and an application thereof. The compound is a compound represented by formula Ia, Ib or Ic. The compound has a good inhibition effect and protein degradation effect on a KRAS_G12D mutant.
|
|
WO/2022/226665A1 |
The present application relates to halo-substituted aza-heteroaryl compounds of Formula (I): (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically accep...
|
|
WO/2022/228535A1 |
Disclosed in the present invention is a preparation method for nicotine and an intermediate thereof, and particularly disclosed is a preparation method for 4-amino-1-pyridin-3-yl-butan-1-one, the method comprising the following steps: su...
|
|
WO/2022/232088A1 |
Provided herein are compounds of Formula (I'), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), or Formula (VIII) and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tau...
|
|
WO/2022/228496A1 |
Provided are compounds of Formula I which can be used as CD38 inhibitors; methods for the production of the compounds; pharmaceutical compositions comprising the compounds; as well as uses and methods for treating a disease mediated by C...
|
|
WO/2022/232632A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2022/229055A1 |
The present invention relates to substituted pyridazinones of the general formula (I), salts or N-oxides thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to their use as h...
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/229405A1 |
The present invention relates to new pyridine-sulfonamide derivatives of formula (I') as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the pr...
|
|
WO/2022/222964A1 |
A compound of formula (I) and a use thereof in medicine. The compound can be used to treat tumor.
|
|
WO/2022/223033A1 |
An SOS1 degrading agent and a preparation method therefor and an application thereof. Specifically, disclosed is a compound represented by formula I: S-L-E(I), wherein L is a linker chain, which connects S and E by means of covalent bond...
|
|
WO/2022/223554A1 |
The present invention relates to new 1H-pyrazole derivatives of formula (I) as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the process for ...
|
|
WO/2022/223376A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2022/225238A1 |
The present invention relates to a heteroaryl derivative compound and a use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against HER2 and EGFR, and thus can be effectively used as a t...
|
|
WO/2022/222965A1 |
Provided are a compound of formula (I) of the present application and the use thereof in medicine, and the compound can be used to treat tumors.
|
